Retromer proteins reduced in Down syndrome and the Dp16 model: impact of APP dose and preclinical studies of a γ-secretase modulator.
Xu-Qiao ChenMariko SawaAnn BeckerDmitry KarachentsevXinxin ZuoKevin D RynearsonRudolph E TanziWilliam C MobleyPublished in: Annals of neurology (2023)
Our studies point to increased APP gene dose as compromising retromer function in DS and suggest causal role for Aβ42 and Aβ40. This article is protected by copyright. All rights reserved.